[1] Pereira E, Cooper HH, Zelaya PG, et al. Concurrent chemoradiation versus radiotherapy alone for the treatment of locally advanced cervical cancer in a low-resource setting[J]. Gynecol Oncol Rep, 2017, 19:50-52. [2] Alberts DS, Blessing JA, Landrum LM, et al.Phase Ⅱ trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer:A gynecologic oncology group study[J]. Gynecol Oncol, 2012, 127(3):451-455. [3] Monk BJ, Sill MW, McMeekin DS,et al.Phase Ⅲ trial of four cisplatin-containing doublet combinations in stage ⅣB, recurrent, or persistent cervical carcinoma:a Gynecologic Oncology Group study[J]. J Clin Oncol, 2009, 27(28):4649-4655. [4] Walker JL, Morrison A, DiSilvestro P, et al. A phase Ⅰ/Ⅱ study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes:a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2009, 112(1):78-84. [5] Kim K, Chie EK, Wu HG, et al. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer[J]. Gynecol Oncol, 2006, 101(3):398-402. [6] Wang X, Shen Y, Zhao Y, et al.Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors:A phase Ⅱ trial[J]. Eur J Surg Oncol, 2015, 41(8):1082-1088. [7] Takatori E, Shoji T, Takada A,et al.A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage Ⅱ cervical squamous cell carcinoma presenting as a bulky mass[J]. Onc Targets Ther, 2016, 9:5651-5657. [8] Huang YT, Wang CC, Tsai CS, et al.Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2012, 84(2):420-427. [9] Chen JL, Huang CY, Huang YS, et al. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy[J]. Acta Obset Gynecol Scand, 2014, 93(7):661-668. [10] Huang YT, Wang CC, Tsai CS, et al.Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2011, 80(2):429-436. [11] Rose PG, Java JJ, Whitney CW, et al.Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation[J]. Gynecol Oncol, 2014, 135(2):208-212. [12] Rose PG.Chemoradiotherapy for cervical cancer[J]. Eur J Cancer, 2002, 38(2):270-278. [13] Chen MF, Tseng CJ, Tseng CC, et al.Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy:comparison with conventional radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2007, 67(5):1438-1444. [14] Duenas-Gonzalez A, Zarba JJ, Patel F, et al.Phase Ⅲ, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage ⅡB to IVA carcinoma of the cervix[J]. J Clin Oncol, 2011, 29(13):1678-1685. [15] Sun W, Wang T, Shi F, et al.Randomized phase Ⅲ trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy[J]. BMC Cancer, 2015, 15:353. [16] 范淑英,王健,刘芸,等.紫杉醇联合卡铂周疗和三周疗法治疗卵巢癌的Meta分析[J]. 解放军医学杂志,2016,41(7):589-597. [17] 李丹明,王黎,孙新臣,等.中晚期宫颈癌适形调强放疗与容积旋转调强技术临床效果比较[J]. 中国医学物理学杂志,2016,33(5):478-480. |